Back

Safety and efficacy of apixaban for the prevention of thromboembolism in adults with congenital heart disease and atrial arrhythmias: a prospective cohort study with historical control comparison

27 August 2023 (11:15 - 12:00)
Organised by: Logo
Congress Presentation Part of: Pharmacotherapy and biomarkers in adult congenital heart disease: do the same rules apply? Adult Congenital Heart Disease (ACHD) ESC Professional Premium Access ESC Congress 2023 European Society of Cardiology

About the speaker

Photo
Doctor Anastasios Kartas

Ippokrateio General Hospital of Athens, Athens (Greece)

6 More presentations in this session

Presentation thumbnail
Dapaglifozin in adults with a systemic right ventricle:initial results from the DAPA-SERVE trial
Doctor M. Abbate (Naples, IT)
Abstract Slides Video
Presentation thumbnail
Prognostic value and determinants of high sensitive cardiac Troponin levels in patients with a systemic right ventricle: insights from the SERVE-Trial
Doctor F. Ruperti Repilado (Basel, CH)
Abstract Slides Video
Presentation thumbnail
Evaluating the safety and long-term efficacy of triple vasodilator therapy for pulmonary arterial hypertension associated with congenital heart disease
Doctor R. Luna (Barcelona, ES)
Abstract Slides Video
Presentation thumbnail
Adults with congenital heart disease and pulmonary arterial hypertension: Quantitative assessment of haemodynamic parameters under disease targeting therapy - A retrospective multicentre analysis
Doctor P. von Stein (Cologne, DE)
Abstract Slides Video
Presentation thumbnail
Efficacy of intravenous iron therapy compared to usual treatment in iron deficient adult cyanotic congenital heart disease patients for improvement in clinical outcomes at three months
Assistant Professor Z. Abdullah (New Delhi, IN)
Abstract Slides Video

Access the full session

Session thumbnail
Pharmacotherapy and biomarkers in adult congenital heart disease: do the same rules apply?

The Event

Event poster

ESC Congress 2023

27 August 2023 11:15 CET
You may be interested in
thumbnail
Congress Presentation
HI-PRO: Apixaban for Extended Treatment of Provoked Venous Thromboembolism
thumbnail
Congress Presentation
Low rates of haemorrhagic stroke, not increased by age, renal/hepatic impairment, concomitant anti-platelet use and high CHA2DS2-VASc scores, in the 4-year follow-up of ETNA-AF-Europe
thumbnail
Congress Session
HOT LINE 5

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources